Skip to main content



Full Agenda (subject to change)

Full Agenda (subject to change)

  • Friday, September 12, 2025
  • 07:30 - 08:00 CEST
    YIM Breakfast Tea & Coffee
  • 08:10 - 09:15 CEST
    YIM Session 1: Pathogenesis of CLL
    Co-Chair: Elisa ten Hacken, PhD – Weill Cornell Medicine
    Co-Chair: Emanuela M. Ghia, PhD – UC San Diego
    YIM
  • 09:15 - 09:35 CEST
    Morning Break
  • 09:35 - 10:45 CEST
    YIM Session 2: Translational Research with Novel Agents and the Impact of the Microenvironment
    Co-Chair: Marek Mraz, MD, PhD – Dept of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Rep.; CEITEC, Masaryk University
    Co-Chair: Alan G. Ramsay, PhD – Lymphoma Immunology Group, Kings College London
    YIM
  • 10:45 - 11:05 CEST
    Morning Break #2
  • 11:05 - 12:00 CEST
    YIM Session 3: T-cell Engaging Therapies in CLL
    Co-Chair: Philip Thompson, MB, BS (Hons) – Peter MacCallum Cancer Centre & Royal Melbourne Hospital; The Sir Peter MaCallum Department of Clinical Oncology, University of Melbourne
    Co-Chair: Erin M. Parry, MD, PhD – Dana-Farber Cancer Institute, Harvard Medical School
    YIM
  • 12:00 - 12:45 CEST
    Lunch
  • 12:45 - 13:50 CEST
    YIM Session 4: Clinical Approach Considerations and Treatment Options in CLL
    Co-Chair: Moritz Fürstenau, MD – Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne and Duesseldorf, German CLL Study Group, Faculty of Medicine and University Hospital Cologne, University of Cologne
    Co-Chair: Elżbieta Iskierka-Jażdżewska, MD – Medical University of Lodz, Copernicus Memorial Hospital, Department of Hematology; Copernicus Memorial Hospital in Lodz, Medical University of Lodz, Department of General Hematology and Internal Medicine
    YIM
  • 13:50 - 14:10 CEST
    Afternoon Break
  • 14:10 - 14:55 CEST
    YIM Keynote, YIM Awards, and Concluding Remarks
    Co-Chair: Bartosz Pula, MD, PhD – Department of Hematology, Medical University of Lodz; Department of General Hematology and Internal Medicine, Copernicus Memorial Hospital
    Co-Chair: Marek Mraz, MD, PhD – Dept of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Rep.; CEITEC, Masaryk University
    YIM
  • 18:30 - 19:30 CEST
    iwCLL Welcome Reception
  • Saturday, September 13, 2025
  • 07:15 - 08:15 CEST
    Breakfast Coffee & Tea
  • 08:40 - 10:15 CEST
    Session 1: Novel Insights Into the Pathogenesis of CLL
    Co-Chair: Catherine Wu, MD – Dana-Farber Cancer Institute, Harvard Medical School
    Co-Chair: Stephan Stilgenbauer, MD – Division of CLL, Internal Medicine III, Ulm University
  • 10:15 - 10:35 CEST
    Morning Break
  • 10:35 - 12:20 CEST
    Session 2: Genomics, Epigenetics, and Proteomics of CLL
    Co-Chair: Thorsten Zenz, MD – University of Zurich
    Co-Chair: Sarka Pospisilova, PhD – Masaryk University and University Hospital Brno
  • 12:20 - 12:50 CEST
    Lunch
  • 13:55 - 15:20 CEST
    Session 3: Immunology and the Tumor Microenvironment
    Co-Chair: Nicholas Chiorazzi, MD – The Feinstein Institutes for Medical Research, Northwell Health System
    Co-Chair: Martina Seiffert, PhD – German Cancer Research Center
  • 15:20 - 15:40 CEST
    Afternoon Break
  • 15:40 - 17:10 CEST
    Session 4: Preclinical Studies of Novel Therapies
    Co-Chair: Paolo Ghia, MD, PhD – Università Vita Salute and IRCCS Ospedale San Raffaele
    Co-Chair: Shih-Shih Chen, PhD – The Feinstein Institutes for Medical Research
  • Sunday, September 14, 2025
  • 07:15 - 20:15 CEST
    Breakfast Coffee & Tea
  • 08:15 - 09:25 CEST
    Session 5: Management of Treatment Lines Throughout the Course of CLL
    Co-Chair: Barbara Eichhorst, MD – Department I of Internal Medicine, University Hospital of Cologne
    Co-Chair: William G. G. Wierda, MD, PhD – The University of Texas MD Anderson Cancer Center
  • 09:25 - 10:40 CEST
    Session 6: How I Treat Double Relapsed/Refractory CLL
    Co-Chair: Jennifer R. Brown, MD, PhD – Dana-Farber Cancer Institute
    Co-Chair: John Seymour, MBBS, PhD, FRACP – Peter MacCallum Cancer Centre & Royal Melbourne Hospital
  • 10:40 - 11:00 CEST
    Morning Break
  • 12:05 - 13:05 CEST
    Session 7: Richter Transformation
    Co-Chair: Gianluca Gaidano, MD, PhD - Co-Chair – University of Eastern Piedmont, Maggiore Charity Hospital
    Co-Chair: Silvia Deaglio, MD, PhD – University of Turin
  • 13:05 - 13:55 CEST
    Lunch
  • 15:00 - 15:55 CEST
    Session 8: Health Maintenance for Patients with CLL
    Co-Chair: Carsten U. Niemann, MD, PhD – Rigshospitalet, Copenhagen University Hospital
    Co-Chair: Brian Koffman, MDCM – CLL Advocates Network, CLL Society
  • 15:50 - 16:50 CEST
    Session 9: CONCURRENT WORKSHOP BREAKOUTS - 3 SESSIONS
  • 17:00 - 18:30 CEST
    Wine & Cheese Poster Session Reception
  • Monday, September 15, 2025
  • 07:15 - 08:15 CEST
    Breakfast Coffee & Tea
  • 08:15 - 09:40 CEST
    Session 10: Novel Therapies for CLL I: Non-Immunological Approaches
    Co-Chair: Jennifer A. Woyach, MD – Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center
    Co-Chair: Francesc Bosch, MD, PhD – Universtitat Autonoma Barcelona, Hospital Universitari Vall d'Hebron
  • 09:40 - 10:00 CEST
    Morning Break
  • 10:00 - 11:30 CEST
    Session 11: Novel Therapies for CLL II: Harnessing the Power of the Immune System to Combat CLL
    Co-Chair: Arnon P. Kater, MD, PhD – Department of Hematology, Amsterdam UMC, Cancer Center Amsterdam, University of Amsterdam, and HOVON
    Co-Chair: Maria Teresa Sabrina Bertilaccio, PhD – The University of Texas MD Anderson Cancer Center
  • 11:30 - 12:20 CEST
    Lunch
  • 12:50 - 14:05 CEST
    Session 12: Patient Experience and CLL in Resource Limited Countries
    Co-Chair: Anna Schuh, MD, PhD – Churchill Hospital, Oxford University
    Co-Chair: Raúl Gabus, MD – Hospital Maciel, ASSE
  • 14:30 - 15:35 CEST
    Session 13: Future Directions and Unmet Needs in CLL
    Co-Chair: Thomas J. Kipps, MD, PhD – UC San Diego, Moores Cancer Center
    Co-Chair: Michael Hallek, MD, PhD – German CLL Study Group, University Hospital of Cologne